Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Johnson and Johnson
Harvard Business School
Mallinckrodt
Baxter

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,828,787

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,828,787
Title:Connector for packaging containing medical fluids and packaging for medical fluids
Abstract: The disclosure relates to a connector for packaging containing medical fluids, in particular infusion or transfusion bags, including a tubular connection part for receiving a spike for the withdrawal of fluid, and having a lower opening on the packaging side and an upper opening on the connection side. A self-sealing membrane, which is pierced by the spike, is located in the connection part. The membrane has an upper, annular section leading into a lower, plate-shaped section, said annular section of the membrane surrounding the spike in a sealing manner, when the latter pierces the plate-shaped section. The membrane acts as a guide for the spike and also reseals the connector, once the spike has been removed.
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Rahimy; Ismael (Friedberg, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:10/514,817
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,828,787
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 7,828,787

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-006 Sep 24, 1996 AP RX Yes No   Start Trial   Start Trial Y   Start Trial
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-007 Sep 24, 1996 AP RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,828,787

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 23 560May 27, 2002
PCT Information
PCT FiledFebruary 24, 2003PCT Application Number:PCT/EP03/01847
PCT Publication Date:December 04, 2003PCT Publication Number: WO03/099191

International Family Members for US Patent 7,828,787

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 469630   Start Trial
Australia 2003208752   Start Trial
Brazil 0311342   Start Trial
Canada 2487551   Start Trial
China 100398084   Start Trial
China 1655750   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Express Scripts
Medtronic
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.